We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CRYOcheck Factor VIII Inhibitor Kit Cleared for Distribution

By LabMedica International staff writers
Posted on 01 Apr 2019
Print article
Image: The CRYOcheck Factor VIII Inhibitor Kit contains standardized components and a validated procedure to prepare patient samples for performing a modified Nijmegen-Bethesda assay (Photo courtesy of Precision BioLogic).
Image: The CRYOcheck Factor VIII Inhibitor Kit contains standardized components and a validated procedure to prepare patient samples for performing a modified Nijmegen-Bethesda assay (Photo courtesy of Precision BioLogic).
Hemophilia A is an inherited bleeding disorder caused by insufficient clotting factor VIII (FVIII) in the blood. People with hemophilia A experience prolonged bleeding, which can lead to permanent joint damage and life-threatening hemorrhages. Prophylaxis, the regular infusion of clotting factor concentrates, is used to prevent bleeds thereby minimizing joint damage.

Unfortunately, up to 30% of people with hemophilia A develop inhibitors, an immune response to treatment with clotting factor concentrates. Inhibitors make it more difficult to manage and treat hemophilia. Apart from access to care and treatment, inhibitors are the most serious challenge in hemophilia care today. While routine blood tests may suggest the presence of anti-FVIII antibodies, specialized testing is important to confirm not only the presence of inhibitors but also the quantitation to effectively adjust treatment.

The presence of factor VIII (FVIII) inhibitors reduces therapy effectiveness and is one of the most complex and costly complications for people with hemophilia A. Because of this, it is important for clinical laboratories to have a testing system that can accurately and precisely quantify FVIII inhibitors in patient samples. Precision BioLogic (Dartmouth, NS, Canada) developed the CRYOcheck Factor VIII Inhibitor Kit to address this challenge.

The kit contains standardized components and a validated procedure to prepare patient samples for performing a modified Nijmegen-Bethesda assay as per the US Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) recommendation. A modified Nijmegen-Bethesda assay is used to determine FVIII inhibitor levels in people with hemophilia A. The kit has received FDA 510(k) clearance from the US Food and Drug Administration (Silver Springs, MD, USA) This clearance follows approvals received from regulatory authorities in Canada, the European Union, Australia, and New Zealand, where the kit was launched in February of this year.

Paul Empey, President & CEO of Precision BioLogic, said, “Enhancing patient care is at the core of everything we do at Precision BioLogic. Our kit will standardize the preparation of patient samples for inhibitor titer measurement. This, in turn, will help laboratories deliver accurate results for the diagnosis and routine monitoring of FVIII inhibitors.”

Related Links:
Precision BioLogic
US Centers for Disease Control and Prevention
US Food and Drug Administration

New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.